331
Views
21
CrossRef citations to date
0
Altmetric
Original Article

Crystal engineering to improve physicochemical properties of mefloquine hydrochloride

, &
Pages 1036-1045 | Received 01 Jun 2009, Accepted 20 Jan 2010, Published online: 05 Nov 2010

References

  • Byrn SR, Pfeiffer RR, Stowell JG. (1999). Solid-state chemistry of drugs. West Lafayette, IN: SSCI.
  • Brittain H, ed. (1999). Polymorphism in pharmaceutical solids, vol. 95. New York: Marcel Dekker.
  • Berge SM, Bighley LD, Monkhouse DC. (1977). Pharmaceutical salts. J Pharm Sci, 66:1–19.
  • Gould PL. (1986). Salt selection for basic drugs. Int J Pharm, 33:201–17.
  • Moneghini M, Kikie I, Voinovich D, Perissutti B, Filipovic-Grcic J. (2001). Processing of carbamazepine-PEG 4000 solid dispersions with supercritical carbon dioxide: Preparation, characterization and in vitro dissolution. Int J Pharm, 222:129–38.
  • Nijlen TV, Brennan K, Mooter VG, Blaton N, Kinget R, Augustijns P. (2003). Improvement of the dissolution rate of Artemisinin by means of supercritical fluid technology and solid dispersions. Int J Pharm, 254:173–81.
  • Hancock BC, Zografi G. (1997). Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci, 86:1–12.
  • Schott H, Kwan LC, Feldman S. (1982). The role of surfactant in the release of very slightly soluble drugs from tablets. J Pharm Bull, 26:118–26.
  • Chiou WL, Riegelman S. (1971). Pharmaceutical applications of solid dispersion systems. J Pharm Sci, 60:1281–302.
  • Christian L, Dressman J. (2000). Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm, 50:47–60.
  • Serajuddin ATM. (1999). Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. J Pharm Sci, 88:1058–66.
  • Henck JO, Griesser UJ, Burger A. (1997). Polymorphie von Arzneistoffen. Eine wirtschaftliche Herausforderung. Pharm Ind, 59:165–9.
  • Veiga F, Teixeria-Dias JJC, Kedezeierewicz F, Sousa A, Maincent P. (1996). Inclusion complexation of tolbutamide with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. Int J Pharm, 129:63–71.
  • Rajewski RA, Stella VJ. (1996). Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci, 85(11):1142–69.
  • Humberstone WN, Charman WN. (1997). Lipid-based vehicles for the oral delivery of poorly soluble drugs. Adv Drug Deliv Rev, 25(1):103–28.
  • Nokhodchi A. (2005). The effect of type and concentration of vehicles on the dissolution rate of a poorly soluble drug (indomethacin) from liquisolid compacts. J Pharm Pharm Sci, 8:18–25.
  • Yadav AV, Yadav VB. (2008). Designing of pharmaceuticals to improve physicochemical properties by spherical crystallization. J Pharm Res, 1(2):97–104.
  • Huang LF, Tong WQ. (2004). Impact of solid state properties on developability assessment of drug candidates. Adv Drug Deliv Rev, 56:321–34.
  • Singhal D, Curatolo W. (2004). Drug polymorphism and dosage form design: Practical perspective. Adv Drug Deliv Rev, 56:335–47.
  • Horter D, Dressman JB. (1997). Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev, 25:3–14.
  • Physician’s Desk Reference. (2003). Electronic library version. MicroMedex (Thompson Healthcare).
  • Lindenberga M, Sabine K, Jennifer BD. (2004). Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm, 58:265–78.
  • Basavoju S, Bostrom D, Velaga SP. (2007). Indomethacin–saccharin co crystal: Design, synthesis and preliminary pharmaceutical characterization. Pharm Res, 25:530–40.
  • Blagden N, de Matas M, Gavan PT, York P. (2007). Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev, 59:617–30.
  • Koji S, Noriyuki T, Ryusuke T, Yoshiki H, Katsuhide T. (2008). Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm Res, 11:2581–92.
  • Julius FR, Sherry LM, Matthew LP, Brain M, MacPhee M, Hector RG, . (2003). Crystal engineering of novel co-crystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc, 125:8456–7.
  • Geoff GZ, Zhang GGZ, Rodger FH, Thomas BB, Xiaochun L. (2007). Efficient co-crystal screening using solution-mediated phase transformation. J Pharm Sci, 96(5):990–5.
  • Andrew VT, Sam Motherwell WD, Jones W. (2006). Physical stability enhancement of theophylline via co crystallization. Int J Pharm, 320:114–23.
  • Magali BH, Matthew LP, Lisa AS, Sherry LM, Vetter A, Guzmán H, . (2007). Performance comparison of a co-crystal of carbamazepine with marketed product. Eur J Pharm Biopharm, 67:112–9.
  • Childs SL, Chyall LJ, Dunlap JT, Smolenskaya VN, Stahly BC, Stahly GP. (2004). Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc, 126:13335–42.
  • Childs SL, Kenneth IH. (2007). Cocrystals of piroxicam with carboxylic acids. Cryst Growth Des, 7(7):1291–304.
  • McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, . (2006). Use of a glutaric acid cocrystal to improve oral bioavailabilty of a low solubility API. Pharm Res, 23:1888–97.
  • Changquan CS, Hou H. (2008). Improving mechanical properties of caffeine and methyl gallate crystals by cocrystallization. Cryst Growth Des, 8(5):1575–9.
  • Foley M, Tilley L. (1998). Quinoline antimalarials: Mechanisms of action and resistance and prospects for new agents. Pharmacol Ther, 79:55–87.
  • British Pharmacopoeia. (1998). Vol. I, 851–2.
  • United States Pharmacopoeia/National Formulary. (2008). Vol. III, 2603–4.
  • Weidekamm E, Rusing G, Caplain H, Sorgel F, Crevoisier C. (1998). Lack of bioequivalence of a generic Mefloquine tablet with the standard product. Eur J Clin Pharmacol, 54:615–9.
  • Baboota S, Khanna R, Karmarkar R, Agarwal SP. (2004). Cyclodextrins based drug delivery systems. In: Jain NK, ed. Progress in controlled and novel drug delivery systems. 1st ed. New Delhi: CBS Publishers and Distributors, 384–404.
  • Higuchi T, Connors KA. (1965). Phase solubility techniques. Adv Anal Chem Instrum, 4:117–212.
  • Stahl PH, Wermuth CG, eds. (2002). Handbook of pharmaceutical salts: Properties, selection, and use. Germany: Wiley Weinheim.
  • Sarah JN, Rodrguez-Spong B, Rodrguez-Hornedo N. (2006). Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst Growth Des, 6(2):592–600.
  • Renato AC, Roger JD, Matthew LP. (2007). Making co-crystals: The utility of ternary phase diagrams. Cryst Growth Des, 7:1223.
  • Sharma BK. (2007). Instrumental methods of chemical analysis. Meerut, Delhi: Goel Publishing House, S194–322.
  • Chatwal GR, Anand SK. (2002). Instrumental methods of chemical analysis. Mumbai: Himalaya Publishing House, 2.29–82.
  • Chatwal GR, Anand SK. (2002). Instrumental methods of chemical analysis. Mumbai: Himalaya Publishing House, 2.701–59.
  • Ryan JA. (1986). Compressed pellet X-ray diffraction monitoring for the optimization of crystallinity in lyophilized solids: Imipenam: Cilastatin sodium case. J Pharm Sci, 75:805–7.
  • Lee J, Lee SC, Acharya G, Chang CJ, Park K. (2003). Hydrotropic solubilization of paclitaxel: Analysis of chemical structures for hydrotropic property. Pharm Res, 20:1022–30.
  • Balasubramanian D, Srinivas V, Gaikar VG, Sharma MM. (1989). Aggregation behavior of hydrotropic compounds in aqueous solution. J Phys Chem, 93:3865–70.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.